Sutton, Scott Channing,Edwards, Martin Paul,Kumpf, Robert Arnold,Kung, Pei-Pei,Mcalpine, Indrawan James,Ninkovic, Sacha,Rui, Eugene Yuanjin,Tatlock, John Howard,Wythes, Martin James,Zehnder, Luke Raym
申请号：
NZ70880113
公开号：
NZ708801A
申请日:
2013.12.05
申请国别(地区):
NZ
年份:
2018
代理人:
摘要：
This invention relates to compounds of general formula (II-A), or a pharmaceutically acceptable salt thereof, wherein: R1 is C1-C4 alkyl or halo； R2 is 5-6 membered heteroaryl optionally substituted by 1 to 3 R32； R3 is H； R4 is H or halo； m is 0 and R5 is absent； each R32 is independently -Cl, -F, -OH, -CH3, -CH2CH3, -CF3, -CH2OH, -CH2OCH3, -OCH3, -OC2H5, -OCF3, -CN, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2, -NHC(O)CH3, -NH2, -NHCH3, -N(CH3)2, cyclopropyl, 4-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl, where said 4-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl are optionally substituted by 1 to 3 halo, C1-C4 alkyl or C1-C4 alkoxy, which are independently selected； X and Z are independently C1-C4 alkyl； and Y is H. The invention also relates to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
